Using MRI Tumour Regression Grade to Guide Treatment in Locally Advanced Rectal Cancer
A UK Phase III Trial Offering Surgery Avoidance or Treatment Intensification Based on Response
Led by Imperial College London · Updated on 2024-10-17
441
Participants Needed
10
Research Sites
521 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of magnetic resonance tumour regression grade mrTRG as a new imaging biomarker to guide treatment decisions for patients with locally advanced rectal cancer. This phase III trial is unique in the UK as it offers a watch and wait approach for patients showing a good response to preoperative treatment, potentially avoiding surgery. The trial aims to validate mrTRGs ability to identify patients who can safely defer surgery and those who may need intensified treatment, thus tailoring care based on MRI findings.
Participants are randomly assigned to one of two groups. The control group receives management according to national guidelines with post-treatment MRI scans interpreted without mrTRG assessment. The intervention group has their post-treatment MRI scans evaluated by specially trained radiologists to assign an mrTRG grade. Patients with a good response mrTRG 1 & 2 are offered a watch and wait approach to avoid surgery, while those with a poor response mrTRG 3-5 have their cases reviewed by a local colorectal multidisciplinary team for further treatment planning and surveillance. Treatment decisions, including chemotherapy use, follow routine clinical practice and are documented but not dictated by the trial.
Participants undergo regular monitoring for up to five years, including routine post-treatment MRI scans following the MERCURY protocol and quality of life questionnaires at registration, 3 years, and 5 years. The study assesses if surgery can be safely avoided after a good MRI response and tracks surgical outcomes, survival, quality of life, and economic impact. Additional evaluations include reproducibility of mrTRG readings, molecular and immunological markers, and circulating tumor DNA to predict relapse. This long-term follow-up aims to improve personalized treatment for rectal cancer patients.
CONDITIONS
Brief Title
Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial
Research Team
C
Caroline Martin
S
Syvella Ellis
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
MRI defined locally advanced rectal carcinoma meeting one or more: mrT3c or higher, mrEMVI positive, mrN1c, or mrCRM positive
Biopsy confirmed adenocarcinoma of the rectum as seen on radiology
Deemed to require preoperative chemoradiotherapy or total neoadjuvant therapy
You will not qualify if you...
Presence of metastatic disease
Contraindications to MRI, radiotherapy, or chemotherapy
Post-treatment MRI performed more than 10 weeks after completion of radiotherapy if given
Previous malignancy within the last 5 years with a recurrence risk greater than 5%
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Variable depending on treatment and response
Participants receive preoperative chemoradiotherapy or total neoadjuvant therapy as per local clinical decisions. Management is guided by MRI tumour regression grade (mrTRG) results, with good responders offered a watch and wait approach and poor responders considered for further treatment.
Visits scheduled according to treatment and imaging assessments
Follow-up
Duration - Up to 5 years
Participants are monitored for up to 5 years after treatment to assess outcomes including surgery avoidance, tumour response, quality of life, and relapse.
Regular follow-up visits over several years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase III Trial Comparing Short-Course Versus Long-Course Radiotherapy Followed by Immunotherapy and Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Phase 2 Study on Safety and Effectiveness of Short Course Radiation and CAPOX Chemotherapy Before Surgery for T2 Rectal Cancer
Open-Label Phase 1 Study of DEM301 to Evaluate Safety and Dose in Adults With Advanced Metastatic Colorectal Cancer
Phase I-II Study of PD1 AB122 and Adenosine Receptor AB928 Antagonists with Chemotherapy After Short-Course Radiation for Rectal Cancer
Phase II Study of Beta-Hydroxybutyrate Supplementation with Short-Course Radiotherapy, Immunotherapy, and CAPEOX Chemotherapy in Locally Advanced Rectal Cancer
Randomized Study Comparing Low Volume Transanal Irrigation by Qufora48 IrriSedo MiniGo with Conservative Treatment in Adults with Low Anterior Resection Syndrome
Phase 2 Study Evaluating Botensilimab With Balstilimab as Adjuvant Treatment for Colorectal Cancer Patients With Persistent Circulating Tumor DNA After Surgery and Chemotherapy
Phase II Open-Label Study of Oral Fruquintinib with FOLFIRI for Adults with Metastatic Colorectal Cancer as Second-Line Treatment
Study of How Rectal Cancer Responds to Standard Chemoradiation and Chemotherapy Before Surgery
Phase II Study of Tucatinib and Trastuzumab Combined with Chemotherapy for Locally Advanced HER2-Positive Rectal Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.